BEAM THERAPEUTICS DL-,01

Beam Therapeutics presented promising clinical data for the in‑vivo BEAM‑302 program in alpha‑1 antitrypsin deficiency at the Cantor conference, with the 60 mg dose reaching the protective threshold in all patients. The company reported $1.2 billion in cash with a financial runway to mid‑2029 and plans multiple launches, including Risto‑cel with a possible BLA filing and launch in the second half of 2027. Beam highlighted its integrated manufacturing infrastructure and an alleged lead of more than two years in base editing, but acknowledged safety monitoring (a transient grade‑3 liver enzyme increase) and intense competitive pressure. » Plus sur de.investing.com

Beam Therapeutics reported comprehensive advances across its base‑editing pipeline, including an expected BLA submission for Risto‑cel in sickle cell disease by the end of 2026 (possibly early 2027) and ongoing recruitment of the approval‑relevant cohort for BEAM‑302 (alpha‑1‑antitrypsin deficiency). An active IND is in place for BEAM‑304 (PKU) and patient screening is planned to start by the end of 2026; BEAM‑301 (GSD1a) could yield first human data in 2026. Management emphasized the platform‑based development approach, agreed regulatory collaboration with the FDA, and funding intended to support operations through mid‑2029. » Plus sur de.investing.com

Beam Therapeutics presented clinical progress of its base‑editing platform at the Wells Fargo Healthcare Conference, notably with BEAM‑302 for alpha‑1 antitrypsin deficiency, which produced AAT levels above the protective threshold in all patients and durability beyond 18 months. Safety events were mostly limited to reversible liver enzyme elevations; there were no signs of liver injury or hospitalization. The company is advancing programs for sickle cell disease (Risto‑Cel, BLA plan by year‑end), PKU (BEAM‑304 IND cleared) and GSD1A, and expects multiple milestones in the next 12–18 months. A $500 million financing facility from Sixth Street is intended to support commercialization of the sickle cell therapy, while competition in the alpha‑1 field is increasing; Beam continues to see a multi‑year lead in base editing. » Plus sur de.investing.com